Drugs / YH002
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05169697 | Feb 2022 → Jul 2023 | neoplasm | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04353102 | Apr 2020 → Sep 2021 | high grade malignant neoplasm | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04353102 ↗ |
| Route | Intravenous | “YH002 will be administered intravenously” NCT04353102 ↗ |